{
    "Trade/Device Name(s)": [
        "ADVIA Centaur Cortisol (COR)"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics, Inc.",
    "510(k) Number": "K192788",
    "Predicate Device Reference 510(k) Number(s)": [
        "K142723"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JFT"
    ],
    "Summary Letter Date": "September 26, 2019",
    "Summary Letter Received Date": "September 30, 2019",
    "Submission Date": "September 26, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.1205"
    ],
    "Regulation Name(s)": [
        "Cortisol (Hydrocortisone and Hydroxycorticosterone) Test System"
    ],
    "Analyte Class(es)": [
        "endocrine",
        "chemistry"
    ],
    "Analyte(s)": [
        "Cortisol"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (EDTA)",
        "Plasma (lithium heparin)",
        "Urine"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur XP system",
        "ADVIA Centaur family of analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Competitive immunoassay",
        "Direct chemiluminescent"
    ],
    "Methodologies": [
        "Immunoassay",
        "Chemiluminescence"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent kit",
        "Calibrator",
        "Diluent",
        "Buffer"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Centaur Cortisol (COR) assay for quantitation of cortisol in serum, plasma (EDTA/lithium heparin), and urine using competitive immunoassay and chemiluminescence technology",
    "Indications for Use Summary": "For in vitro diagnostic use in the quantitative determination of cortisol in serum, plasma (EDTA and lithium heparin), and urine to aid in the diagnosis and treatment of adrenal gland disorders",
    "fda_folder": "Clinical Chemistry"
}